Addressing Neurologic Toxicities in CAR-T Therapy: Monitoring, Management, and Patient Communication
The discussion focuses on monitoring and managing neurologic toxicities like ICANS in CAR-T therapy, highlighting tools for early detection, effective management strategies, and approaches to communicating risks with patients and caregivers.
Video content above is prompted by the following:
- Neurologic toxicities, such as ICANS, pose unique challenges. How do you approach monitoring and management of these events in your practice?
- What tools or assessment methods help you identify early signs of neurotoxicity?
- How do you communicate these risks to patients and their caregivers?
Recent Videos
Related Content
